Sugi Predict

Sugi Predict / Compounds / SCHEMBL674052

SCHEMBL674052

SCHEMBL674052

C[C@](C(=O)O)(c1ccccc1)N(c1ccccc1)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.44
▸ MAPT P10636 1/20 0.44
▸ MEN1 O00255 3/20 0.43
▸ CYP2C19 P33261 2/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ HIF1A Q16665 1/20 0.42
▸ CYP1A2 P05177 2/20 0.42
▸ HDAC3 O15379 1/20 0.41
▸ HDAC4 P56524 1/20 0.41
▸ HDAC1 Q13547 1/20 0.41
▸ HDAC7 Q8WUI4 1/20 0.41
▸ HDAC2 Q92769 1/20 0.41
▸ HDAC10 Q969S8 1/20 0.41
▸ HDAC11 Q96DB2 1/20 0.41
▸ HDAC8 Q9BY41 1/20 0.41
▸ HDAC6 Q9UBN7 1/20 0.41
▸ HDAC9 Q9UKV0 1/20 0.41
▸ HDAC5 Q9UQL6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6285599 1.00 KMT2A (0.44) KMT2AMAPTMEN1CYP2C19CYP3A4
SCHEMBL4799382 0.79 KMT2A (0.40) KMT2AMAPTMEN1CYP2C19CYP3A4
SCHEMBL2089572 0.79 CYP1A2 (0.50) KMT2AMAPTCYP2C19CYP3A4HIF1A
SCHEMBL2089573 0.79 CYP1A2 (0.50) KMT2AMAPTCYP2C19CYP3A4HIF1A
SCHEMBL754265 0.79 CYP1A2 (0.50) KMT2AMAPTCYP2C19CYP3A4HIF1A
SCHEMBL4894696 0.78 KCNN4 (0.42) KMT2AMAPTMEN1CYP2C19CYP3A4
SCHEMBL4893317 0.78 KCNN4 (0.42) KMT2AMAPTMEN1CYP2C19CYP3A4
SCHEMBL3381201 0.78 KMT2A (0.45) KMT2AMAPTMEN1CYP2C19CYP3A4
SCHEMBL288100 0.78 MAPT (0.45) KMT2AMAPTCYP2C19CYP3A4HIF1A
SCHEMBL9437359 0.77 KMT2A (0.47) KMT2AMAPTMEN1CYP2C19CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250332293-A1 METHOD FOR MANUFACTURING BIOCOMPATIBLE NANOPARTICLES WITH A PEPTIDE CORE EXHIBITING SECOND- AND THIRD-HARMONIC SIGNAL GENERATION Pantazis, Periklis (CH) 2025-10-30 — — US claimed
EP-4070801-A1 COMPOSITIONS OF INSULIN AND CHROMIUM FOR THE TREATMENT AND PREVENTION OF DIABETES, HYPOGLYCEMIA AND RELATED DISORDERS Nutrition 21, LLC (US) 2022-10-12 — — EP claimed
EP-3518986-B1 BIODEGRADABLE, SECOND-HARMONIC-GENERATING NANOPROBE FOR BIOMEDICAL IMAGING APPLICATIONS MAX PLANCK GESELLSCHAFT (DE) 2021-12-15 — — EP claimed
US-20210356396-A1 BIODEGRADABLE, SECOND-HARMONIC-GENERATING NANOPROBE FOR BIOMEDICAL IMAGING APPLICATIONS Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. (CH) 2021-11-18 — — US claimed
EP-3518986-A1 BIODEGRADABLE, SECOND-HARMONIC-GENERATING NANOPROBE FOR BIOMEDICAL IMAGING APPLICATIONS ETH Zürich (CH) 2019-08-07 — — EP claimed
EP-2448412-B1 CHROMIUM COMPLEXES AS ENHANCERS OF BRAIN GLUCOSE TRANSPORTERS JDS THERAPEUTICS LLC (US) 2019-05-01 — — EP claimed
WO-2018060378-A1 BIODEGRADABLE, SECOND-HARMONIC-GENERATING NANOPROBE FOR BIOMEDICAL IMAGING APPLICATIONS ETH Zürich (CH) 2018-04-05 — — WO claimed
WO-2004094462-A2 METHODS OF PEPTIDE PREPARATION LYTIX BIOPHARMA AS (NO) 2004-11-04 — — WO claimed
EP-1003771-A1 LINEAR PEPTIDES DERIVED FROM ANTIBIOTIC PEPTIDES, PREPARATION AND USE FOR VECTORING ACTIVE SUBSTANCES Synt:em (S.A.) (FR) 2000-05-31 — — EP claimed
WO-1999007728-A2 LINEAR PEPTIDES DERIVED FROM ANTIBIOTIC PEPTIDES, PREPARATION AND USE FOR VECTORING ACTIVE SUBSTANCES SYNT:EM (S.A.) (FR) 1999-02-18 — — WO claimed
EP-0331404-A2 Method for producing tropane alkaloid SEITAIKINOU RIYOU KAGAKUHIN SHINSEIZOUGIJUTSU KENKYU KUMIAI (JP) 1989-09-06 — — EP claimed
JP-2020291-A — — None — — JP disclosed
US-20250332293-A1 METHOD FOR MANUFACTURING BIOCOMPATIBLE NANOPARTICLES WITH A PEPTIDE CORE EXHIBITING SECOND- AND THIRD-HARMONIC SIGNAL GENERATION Pantazis, Periklis (CH) 2025-10-30 — — US disclosed
US-20250206776-A1 ENZYME-INSTRUCTED SELF-ASSEMBLY OF PEPTIDES CONTAINING N-TERMINAL PHOSPHO-AROMATIC CAPPING MOTIF, AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2025-06-26 — — US disclosed
US-20250122468-A1 BIOINK FOR REPRODUCIBLE PRODUCTION OF 3D TUMOR TISSUE SCAFFOLDS Rise Research Institutes of Sweden AB (SE) 2025-04-17 — — US disclosed
US-6011008-A Conjugates of biologically active substances YISSUM RESEARCH DEVELOPEMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2000-01-04 — — US disclosed
WO-1999007728-A2 LINEAR PEPTIDES DERIVED FROM ANTIBIOTIC PEPTIDES, PREPARATION AND USE FOR VECTORING ACTIVE SUBSTANCES SYNT:EM (S.A.) (FR) 1999-02-18 — — WO disclosed
JP-H0220291-A PRODUCTION OF TROPANE-TYPE ALKALOID SEITAI KINOU RIYOU KAGAKUHIN SHINSEIZOU GIJUTSU KENKYU KUMIAI 1990-01-23 — — JP disclosed
EP-0331404-A2 Method for producing tropane alkaloid SEITAIKINOU RIYOU KAGAKUHIN SHINSEIZOUGIJUTSU KENKYU KUMIAI (JP) 1989-09-06 — — EP disclosed
JP-H00220291-A — — 0001-01-01 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250206776-A1 ENZYME-INSTRUCTED SELF-ASSEMBLY OF PEPTIDES CONTAINING N-TERMINAL PHOSPHO-AROMATIC CAPPING MOTIF, AND USES THEREOF ANPEP, DNPEP, PTMS KMT2A 2907/4885MAPT 1867/4885MEN1 3930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.